Post-marketing pharmacovigilance systems play a key role in the assessment of drug risk/benefit profile, however underreporting, selective reporting and the notoriety bias can influence the early detection of new signals and their interpretation. This analysis also emphasised the importance of adopting appropriate risk communication strategies as a crucial part of health policy, agreed by health regulatory bodies, drug manufacturers and doctors, ensuring in the meantime independent and appropriate information to the patients.
The influence of Notoriety Bias on ADR Spontaneous Rate
G. P. Velo;L. Magro;I. Meneghelli;A. Conforti;
2007-01-01
Abstract
Post-marketing pharmacovigilance systems play a key role in the assessment of drug risk/benefit profile, however underreporting, selective reporting and the notoriety bias can influence the early detection of new signals and their interpretation. This analysis also emphasised the importance of adopting appropriate risk communication strategies as a crucial part of health policy, agreed by health regulatory bodies, drug manufacturers and doctors, ensuring in the meantime independent and appropriate information to the patients.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
